Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Non-germline genetically engineered mouse models for translational cancer research

Key Points

  • Genetically engineered mouse models (GEMMs) have been invaluable in advancing our knowledge of tumour biology. However, accelerated cancer gene discovery through large-scale cancer genomics and an increasing desire to use GEMMs for preclinical therapeutic studies have strained the capacity of germline GEMMs.

  • Non-germline genetic engineering approaches allow for accelerated and flexible genetic manipulation of models.

  • Chimeric models develop tumours in the context of normal stroma, with reduced timelines and mouse housing cost.

  • Transplantation models allow flexible and speedy manipulation of tissue stem and/or progenitor cells with multiple genetic tools (such as knock out, transgenes and RNA interference).

  • Human donor tissue models (or human in mouse models) allow the de novo development of primary human tumours in mouse stroma by manipulating primary human cells.

  • Therapeutic studies in vivo benefit from the wealth of complex GEMM and non-GEMM models to guide drug discovery.

Abstract

Genetically engineered mouse models (GEMMs) of cancer have affected virtually all areas of cancer research. However, the accelerated discovery of new cancer genes emerging from large-scale cancer genomics and new chemical entities pouring from the drug discovery pipeline have strained the capacity of traditional germline mouse models to provide crucial insights. This Review introduces new approaches to modelling cancer, with emphasis on a growing collection of non-germline GEMMs (nGEMMs). These offer flexibility, speed and uniformity at reduced costs, thus paving the way for much needed throughput and practical preclinical therapeutic testing models.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: Conditional genetically engineered mouse models (GEMMs).
Figure 2: Chimeric model generation.
Figure 3: Human in mouse transplantation models.

References

  1. 1

    Sharpless, N. E. & Depinho, R. A. The mighty mouse: genetically engineered mouse models in cancer drug development. Nature Rev. Drug Discov. 5, 741–754 (2006).

    CAS  Article  Google Scholar 

  2. 2

    Huettner, C. S., Zhang, P., Van Etten, R. A. & Tenen, D. G. Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nature Genet. 24, 57–60 (2000).

    CAS  PubMed  Article  Google Scholar 

  3. 3

    Roberts, R. B. et al. Importance of epidermal growth factor receptor signaling in establishment of adenomas and maintenance of carcinomas during intestinal tumorigenesis. Proc. Natl Acad. Sci. USA 99, 1521–1526 (2002).

    CAS  PubMed  Article  Google Scholar 

  4. 4

    Jonkers, J. & Berns, A. Conditional mouse models of sporadic cancer. Nature Rev. Cancer 2, 251–265 (2002).

    CAS  Article  Google Scholar 

  5. 5

    Chin, L. et al. Essential role for oncogenic Ras in tumour maintenance. Nature 400, 468–472 (1999). The first conditional transgenic mouse model to demonstrate solid tumour regression on extinction of the initiating oncogene.

    CAS  PubMed  Article  Google Scholar 

  6. 6

    Su, L. K. et al. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science 256, 668–670 (1992).

    CAS  PubMed  Article  Google Scholar 

  7. 7

    Corpet, D. E. & Pierre, F. How good are rodent models of carcinogenesis in predicting efficacy in humans? A systematic review and meta-analysis of colon chemoprevention in rats, mice and men. Eur. J. Cancer 41, 1911–1922 (2005).

    CAS  PubMed  Article  Google Scholar 

  8. 8

    Jimeno, A. et al. A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development. Mol. Cancer Ther. 8, 310–314 (2009).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  9. 9

    Edelmann, W. et al. Mutation in the mismatch repair gene Msh6 causes cancer susceptibility. Cell 91, 467–477 (1997).

    CAS  PubMed  Article  Google Scholar 

  10. 10

    Meuwissen, R., Linn, S. C., van der Valk, M., Mooi, W. J. & Berns, A. Mouse model for lung tumorigenesis through Cre/lox controlled sporadic activation of the K-Ras oncogene. Oncogene 20, 6551–6558 (2001).

    CAS  PubMed  Article  Google Scholar 

  11. 11

    Tuveson, D. A. et al. Endogenous oncogenic K-rasG12D stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell 5, 375–387 (2004).

    CAS  PubMed  Article  Google Scholar 

  12. 12

    Dinulescu, D. M. et al. Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nature Med. 11, 63–70 (2005).

    CAS  PubMed  Article  Google Scholar 

  13. 13

    Flesken-Nikitin, A., Choi, K. C., Eng, J. P., Shmidt, E. N. & Nikitin, A. Y. Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium. Cancer Res. 63, 3459–3463 (2003).

    CAS  PubMed  Google Scholar 

  14. 14

    Engelman, J. A. et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nature Med. 14, 1351–1356 (2008).

    CAS  PubMed  Article  Google Scholar 

  15. 15

    Indra, A. K. et al. Temporally-controlled site-specific mutagenesis in the basal layer of the epidermis: comparison of the recombinase activity of the tamoxifen-inducible Cre-ER(T) and Cre-ER(T2) recombinases. Nucleic Acids Res. 27, 4324–4327 (1999).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  16. 16

    Bosenberg, M. et al. Characterization of melanocyte-specific inducible Cre recombinase transgenic mice. Genesis 44, 262–267 (2006).

    CAS  PubMed  Article  Google Scholar 

  17. 17

    Dankort, D. et al. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nature Genet. 41, 544–552 (2009).

    CAS  Article  Google Scholar 

  18. 18

    Dhomen, N. et al. Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell 15, 294–303 (2009).

    CAS  Article  Google Scholar 

  19. 19

    Schmidt-Supprian, M., Wunderlich, F. T. & Rajewsky, K. Excision of the Frt-flanked neoR cassette from the CD19cre knock-in transgene reduces Cre-mediated recombination. Transgenic Res. 16, 657–660 (2007).

    CAS  PubMed  Article  Google Scholar 

  20. 20

    Gossen, M. et al. Transcriptional activation by tetracyclines in mammalian cells. Science 268, 1766–1769 (1995).

    CAS  PubMed  Article  Google Scholar 

  21. 21

    Felsher, D. W. & Bishop, J. M. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol. Cell 4, 199–207 (1999).

    CAS  PubMed  Article  Google Scholar 

  22. 22

    Jain, M. et al. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science 297, 102–104 (2002).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  23. 23

    D'Cruz, C. M. et al. c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations. Nature Med. 7, 235–239 (2001).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  24. 24

    Rao, G. et al. Sonic hedgehog and insulin-like growth factor signaling synergize to induce medulloblastoma formation from nestin-expressing neural progenitors in mice. Oncogene 23, 6156–6162 (2004).

    CAS  Article  PubMed  Google Scholar 

  25. 25

    Shih, A. H. et al. Dose-dependent effects of platelet-derived growth factor-B on glial tumorigenesis. Cancer Res. 64, 4783–4789 (2004).

    CAS  PubMed  Article  Google Scholar 

  26. 26

    Momota, H., Nerio, E. & Holland, E. C. Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo. Cancer Res. 65, 7429–7435 (2005).

    CAS  PubMed  Article  Google Scholar 

  27. 27

    Pao, W., Klimstra, D. S., Fisher, G. H. & Varmus, H. E. Use of avian retroviral vectors to introduce transcriptional regulators into mammalian cells for analyses of tumor maintenance. Proc. Natl Acad. Sci. USA 100, 8764–8769 (2003).

    CAS  PubMed  Article  Google Scholar 

  28. 28

    Regales, L. et al. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J. Clin. Invest. 119, 3000–3010 (2009).

    CAS  PubMed  PubMed Central  Google Scholar 

  29. 29

    Marumoto, T. et al. Development of a novel mouse glioma model using lentiviral vectors. Nature Med. 15, 110–116 (2009).

    CAS  PubMed  Article  Google Scholar 

  30. 30

    Singh, M et al. Modelling therapeutic responses in Kras mutant cancers using genetically engineered mouse models. Nature Biotechnol. 23 May 2010 (doi: 10.103a8/nbt.1640).

  31. 31

    Zhou, Y. et al. Chimeric mouse tumor models reveal differences in pathway activation between ERBB family- and KRAS-dependent lung adenocarcinomas. Nature Biotechnol. 28, 71–78 (2010). EGFR- but not KRAS-driven chimeric lung adenocarcinomas generated from engineered ESCs show near-complete tumour regression on treatment with an EGFR inhibitor.

    CAS  Article  Google Scholar 

  32. 32

    Wu, M. et al. Dissecting genetic requirements of human breast tumorigenesis in a tissue transgenic model of human breast cancer in mice. Proc. Natl Acad. Sci. USA 106, 7022–7027 (2009). Normal breast cancer cells grown as organoids produce orthotopic tumours in mice with histopathological features that more closely resemble the primary tumour than the features of tumours generated from cells cultured on plastic.

    CAS  PubMed  Article  Google Scholar 

  33. 33

    Schmitt, C. A., McCurrach, M. E., de Stanchina, E., Wallace-Brodeur, R. R. & Lowe, S. W. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev. 13, 2670–2677 (1999).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  34. 34

    Zender, L. et al. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 125, 1253–1267 (2006). Liver progenitor cells harvested from embryonic mice and engineered with various oncogenes produce carcinomas orthotopically in syngeneic hosts and can be used to identify new oncogenes.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  35. 35

    Pear, W. S. et al. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood 92, 3780–3792 (1998).

    CAS  PubMed  Google Scholar 

  36. 36

    Le, L. Q., Shipman, T., Burns, D. K. & Parada, L. F. Cell of origin and microenvironment contribution for NF1-associated dermal neurofibromas. Cell Stem Cell 4, 453–463 (2009).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  37. 37

    Trimboli, A. J. et al. Pten in stromal fibroblasts suppresses mammary epithelial tumours. Nature 461, 1084–1091 (2009).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  38. 38

    Paik, J. H. et al. FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell 128, 309–323 (2007).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  39. 39

    Jongsma, J. et al. A conditional mouse model for malignant mesothelioma. Cancer Cell 13, 261–271 (2008).

    CAS  PubMed  Article  Google Scholar 

  40. 40

    Watters, J. W. et al. De novo discovery of a γ-secretase inhibitor response signature using a novel in vivo breast tumor model. Cancer Res. 69, 8949–8957 (2009).

    CAS  PubMed  Article  Google Scholar 

  41. 41

    Hemann, M. T. et al. An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo. Nature Genet. 33, 396–400 (2003).

    CAS  PubMed  Article  Google Scholar 

  42. 42

    Takada, A. & Takada, Y. Proliferation of donor hematopoietic cells in lethally irradiated host mice. Transplantation 13, 276–280 (1972).

    CAS  PubMed  Article  Google Scholar 

  43. 43

    Schmitt, C. A. et al. Dissecting p53 tumor suppressor functions in vivo. Cancer Cell 1, 289–298 (2002).

    CAS  Article  PubMed  Google Scholar 

  44. 44

    Schwaller, J. et al. Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes. EMBO J. 17, 5321–5333 (1998).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  45. 45

    Fridman, J. S. et al. Tumor promotion by Mdm2 splice variants unable to bind p53. Cancer Res. 63, 5703–5706 (2003).

    CAS  PubMed  Google Scholar 

  46. 46

    Wendel, H. G. et al. Dissecting eIF4E action in tumorigenesis. Genes Dev. 21, 3232–3237 (2007).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  47. 47

    Phan, V. T. et al. Cooperation of cytokine signaling with chimeric transcription factors in leukemogenesis: PML-retinoic acid receptor alpha blocks growth factor-mediated differentiation. Mol. Cell. Biol. 23, 4573–4585 (2003).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  48. 48

    Hemann, M. T. et al. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature 436, 807–811 (2005).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  49. 49

    Schmitt, C. A., Rosenthal, C. T. & Lowe, S. W. Genetic analysis of chemoresistance in primary murine lymphomas. Nature Med. 6, 1029–1035 (2000).

    CAS  PubMed  Article  Google Scholar 

  50. 50

    Zuber, J. et al. Mouse models of human AML accurately predict chemotherapy response. Genes Dev. 23, 877–889 (2009). nGEMM leukaemia models driven by an MLLT1 gene fusion, but not ones driven by a RUNX1 gene fusion, are refractory to chemotherapy, mirroring the prognostic course of therapy in patients harbouring either of the respective fusions.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  51. 51

    Wendel, H. G. et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428, 332–337 (2004).

    CAS  Article  Google Scholar 

  52. 52

    Mullighan, C. G., Williams, R. T., Downing, J. R. & Sherr, C. J. Failure of CDKN2A/B (INK4A/B-ARF)-mediated tumor suppression and resistance to targeted therapy in acute lymphoblastic leukemia induced by BCR-ABL. Genes Dev. 22, 1411–1415 (2008).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  53. 53

    Lauchle, J. O. et al. Response and resistance to MEK inhibition in leukaemias initiated by hyperactive Ras. Nature 461, 411–414 (2009).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  54. 54

    Varticovski, L. et al. Accelerated preclinical testing using transplanted tumors from genetically engineered mouse breast cancer models. Clin. Cancer Res. 13, 2168–2177 (2007).

    CAS  PubMed  Article  Google Scholar 

  55. 55

    Rottenberg, S. et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc. Natl Acad. Sci. USA 105, 17079–17084 (2008).

    CAS  PubMed  Article  Google Scholar 

  56. 56

    Rottenberg, S. et al. Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proc. Natl Acad. Sci. USA 104, 12117–12122 (2007).

    CAS  PubMed  Article  Google Scholar 

  57. 57

    Evers, B. et al. A tissue reconstitution model to study cancer cell-intrinsic and -extrinsic factors in mammary tumourigenesis. J. Pathol. 220, 34–44 (2010).

    CAS  PubMed  Article  Google Scholar 

  58. 58

    Bachoo, R. M. et al. Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell 1, 269–277 (2002).

    CAS  PubMed  Article  Google Scholar 

  59. 59

    Zindy, F. et al. Genetic alterations in mouse medulloblastomas and generation of tumors de novo from primary cerebellar granule neuron precursors. Cancer Res. 67, 2676–2684 (2007).

    CAS  PubMed  Article  Google Scholar 

  60. 60

    Xing, D. & Orsulic, S. A mouse model for the molecular characterization of brca1-associated ovarian carcinoma. Cancer Res. 66, 8949–8953 (2006).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  61. 61

    Xue, W. et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445, 656–660 (2007).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  62. 62

    Alcantara Llaguno, S. R., Chen, J. & Parada, L. F. Signaling in malignant astrocytomas: role of neural stem cells and its therapeutic implications. Clin. Cancer Res. 15, 7124–7129 (2009).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  63. 63

    Uren, A. G. et al. Large-scale mutagenesis in p19ARF- and p53-deficient mice identifies cancer genes and their collaborative networks. Cell 133, 727–741 (2008).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  64. 64

    Starr, T. K. et al. A transposon-based genetic screen in mice identifies genes altered in colorectal cancer. Science 323, 1747–1750 (2009).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  65. 65

    Zender, L. et al. An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell 135, 852–864 (2008).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  66. 66

    Witt, A. E. et al. Functional proteomics approach to investigate the biological activities of cDNAs implicated in breast cancer. J. Proteome Res. 5, 599–610 (2006).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  67. 67

    Bric, A. et al. Functional identification of tumor-suppressor genes through an in vivo RNA interference screen in a mouse lymphoma model. Cancer Cell 16, 324–335 (2009).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  68. 68

    Meacham, C. E., Ho, E. E., Dubrovsky, E., Gertler, F. B. & Hemann, M. T. In vivo RNAi screening identifies regulators of actin dynamics as key determinants of lymphoma progression. Nature Genet. 41, 1133–1137 (2009).

    CAS  Article  PubMed  Google Scholar 

  69. 69

    Wattel, E. et al. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 84, 3148–3157 (1994).

    CAS  PubMed  Google Scholar 

  70. 70

    Jiang, H. et al. The combined status of ATM and p53 link tumor development with therapeutic response. Genes Dev. 23, 1895–1909 (2009).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  71. 71

    Hoffman, R. M. Orthotopic metastatic (MetaMouse) models for discovery and development of novel chemotherapy. Methods Mol. Med. 111, 297–322 (2005).

    CAS  PubMed  Google Scholar 

  72. 72

    Maser, R. S. et al. Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature 447, 966–971 (2007).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  73. 73

    Artandi, S. E. & DePinho, R. A. Telomeres and telomerase in cancer. Carcinogenesis 31, 9–18 (2009).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  74. 74

    Rudolph, K. L. Telomeres and telomerase influence the course of human diseases, aging and carcinogenesis. Curr. Mol. Med. 5, 133–134 (2005).

    CAS  PubMed  Article  Google Scholar 

  75. 75

    Farazi, P. A., Glickman, J., Horner, J. & Depinho, R. A. Cooperative interactions of p53 mutation, telomere dysfunction, and chronic liver damage in hepatocellular carcinoma progression. Cancer Res. 66, 4766–4773 (2006).

    CAS  PubMed  Article  Google Scholar 

  76. 76

    Olive, K. P. et al. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 119, 847–860 (2004).

    CAS  Article  Google Scholar 

  77. 77

    Fan, H., Oro, A. E., Scott, M. P. & Khavari, P. A. Induction of basal cell carcinoma features in transgenic human skin expressing Sonic Hedgehog. Nature Med. 3, 788–792 (1997). The first in a series of papers using normal human skin cells to orthotopically generate carcinomas and melanomas in mice by grafting with stromal elements.

    CAS  PubMed  Article  Google Scholar 

  78. 78

    Chudnovsky, Y., Adams, A. E., Robbins, P. B., Lin, Q. & Khavari, P. A. Use of human tissue to assess the oncogenic activity of melanoma-associated mutations. Nature Genet. 37, 745–749 (2005).

    CAS  PubMed  Article  Google Scholar 

  79. 79

    Khavari, P. A. Modelling cancer in human skin tissue. Nature Rev. Cancer 6, 270–280 (2006).

    CAS  Article  Google Scholar 

  80. 80

    Lazarov, M. et al. CDK4 coexpression with Ras generates malignant human epidermal tumorigenesis. Nature Med. 8, 1105–1114 (2002).

    CAS  PubMed  Article  Google Scholar 

  81. 81

    Atillasoy, E. S. et al. UVB induces atypical melanocytic lesions and melanoma in human skin. Am. J. Pathol. 152, 1179–1186 (1998).

    CAS  PubMed  PubMed Central  Google Scholar 

  82. 82

    Barabe, F., Kennedy, J. A., Hope, K. J. & Dick, J. E. Modeling the initiation and progression of human acute leukemia in mice. Science 316, 600–604 (2007). A HIM leukaemia model using human cord blood transduced with an MLLT1 gene fusion can be used to identify LICs.

    CAS  PubMed  Article  Google Scholar 

  83. 83

    Kuperwasser, C. et al. Reconstruction of functionally normal and malignant human breast tissues in mice. Proc. Natl Acad. Sci. USA 101, 4966–4971 (2004).

    CAS  PubMed  Article  Google Scholar 

  84. 84

    Rong, S. et al. Tumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factor. Mol. Cell. Biol. 12, 5152–5158 (1992).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  85. 85

    Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57–70 (2000).

    CAS  Article  Google Scholar 

  86. 86

    Vogelstein, B. & Kinzler, K. W. Cancer genes and the pathways they control. Nature Med. 10, 789–799 (2004).

    CAS  PubMed  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Lynda Chin.

Ethics declarations

Competing interests

J. H. is an employee of AVEO Pharmaceuticals.

Related links

Related links

DATABASES

National Cancer Institute Drug Dictionary 

AV-412

bevacizumab

BEZ235

cyclophosphamide

doxycycline

erlotinib

perifosine

tetracycline

trastuzumab

OMIM

Li–Fraumeni syndrome

Pathway Interaction Database 

p53

FURTHER INFORMATION

Lynda Chin's homepage

Glossary

Germline model

Mouse model that carries genetic modifications in its germline and which is maintained through breeding.

Inducible model

Mouse model that activates the expression of a transgene through a transactivator transgene that is, tTA or rtTA.

Non-germline GEMM (nGEMM)

Mouse model that carries genetic modifications in some of its somatic cells but not in the germline cells. Each model has to be individually generated through, for example, transplantation and injection.

Mosaic model

Germline model that acquires modifications of the germline genetic modification in some of its somatic cells.

Conditional GEMM

Model that acquires an activation or inactivation of the original genetic modification in somatic cells through the temporal or spatial expression of a modifier such as Cre.

Chimeric model

Mouse model that has been generated by ESC manipulation followed by the injection of these cells into a pre-implantation embryo. The resulting chimeric animal is the model animal.

Transplantation model

Mouse model in which part of a tissue is modified by transplanting tissue stem cells that carry genetic modifications.

Human in mouse (HIM) model

Transplantation model in which the transplanted cells are human tissue stem cells.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Heyer, J., Kwong, L., Lowe, S. et al. Non-germline genetically engineered mouse models for translational cancer research. Nat Rev Cancer 10, 470–480 (2010). https://doi.org/10.1038/nrc2877

Download citation

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing